Takeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's Disease
By Dean Seal
Takeda Pharmaceutical said the U.S. Food and Drug Administration has approved subcutaneous administration of Entyvio as a maintenance therapy for adults with Crohn's disease.
The company said Thursday that the regulatory approval is specifically for subcutaneous administration in adults with moderately to severely active Crohn's after induction therapy with intravenous Entyvio.
Subcutaneous administration of the treatment was approved in September for maintenance therapy of adults with moderately to severely active ulcerative colitis.
The treatment is available in the U.S. as a single-dose prefilled pen, known as the Entyvio Pen.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
April 18, 2024 19:34 ET (23:34 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks